Abbott plans to expand the monitoring capabilities of its FreeStyle Libre device to enable people to make healthier decisions. The platform uses a disk that is adhered to the skin and uses wireless communication with the patient's smartphone to transfer data into an app where they can monitor their glucose levels in real time without the need for finger prick blood tests. This wearable technology is now being expanded to other areas of biohealth monitoring.
January 7, 2022 — Abbott announced it is developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body such as glucose, ketones, and lactate to help people better understand their general health and take action. Over the past year, the company has been moving toward increasing use of wearable patient monitoring technologies and integration of artificial intelligence (AI) in consumer and its clinical products, including cardiology devices.
Abbott became the first healthcare company to ever present a keynote at the Consumer Electronics Show (CES), the world's largest and most influential tech event, which is taking place in Las Vegas this week.
"Technology gives us the power to digitize, decentralize and democratize healthcare, create a shared language between you and your doctor – and put more control of your health in your hands," explained Abbott Chairman and Chief Executive Officer Robert B. Ford. "We're creating a future that will bring you and your loved ones care that's more personal and precise. It's happening right now. And its potential is no less than incredible."
During the keynote, the company announced it is developing a new category of consumer biowearables called Lingo. These wearable devices are being designed to translate your body's unique language into actionable data to help you track and measure your general health and wellness. The sensor technology is being designed to track key signals in the body such as glucose, ketones and lactate, and could also be used one day to track alcohol levels.
"This will be like having a window into your body," Ford said. "It's science that you will be able to access any time so you can understand what your body is telling you and what it needs. Our vision is that Lingo will go far beyond today's wearables for consumers to help you proactively manage your health, nutrition and athletic performance."
Lingo extends the Abbott sensing technology platform that Abbott pioneered in 2014 for people with diabetes, allowing people to continuously monitor their glucose levels with a small sensor on the back of the upper arm. Actress and comedian Sherri Shepherd shared live on the CES stage how FreeStyle Libre 2 changed her life, giving her glucose readings, right on her smartphone, unique to her body so she can make healthier decisions.
The platform uses a disk that is adhered to the skin and uses wireless communication with the patient's smartphone to transfer data into an app where they can monitor their glucose levels in real time without the need for finger prick blood tests. This technology is now being expanded to other areas of health monitoring.
Abbott built this technology platform to develop a product designed for athletes with the 2020 launch of Libre Sense Glucose Sport Biowearable in Europe. Elite athletes, like marathon world record holder Eliud Kipchoge, use this biowearable to optimize how they fuel their bodies for rigorous training. Lingo aims to expand glucose monitoring to people looking to manage their weight, sleep better, improve energy and think clearer.
Abbott is designing Lingo to measure other biomarkers beyond glucose in the future. A ketone biowearable is being developed to track ketones continuously, see how fast you are getting into ketosis, and understand exactly what keeps you there by providing insights on dieting and weight loss. A lactate biowearable is in development to track continuous lactate build up during exercise, which can be used as an indicator of athletic performance.
CES Presentation of How Wearables and Implantable Devices Changed Patient Lives
Beyond those who demonstrated the human impact of Abbott's sensors, Mr. Ford was joined on stage by people whose lives were impacted by Abbott devices, partners who rallied to provide seamless and safe travel experiences and other visionaries in the industry.
Tyrone Morris, a heart failure patient who was given six months to live, shared his story of how he beat the odds thanks to three separate Abbott devices: HeartMate 3, CardioMEMS and an implantable defibrillator. Today, Morris owns a barbecue catering business and food trucks in Humble, Texas, where he specializes in low-sodium recipes.
United Airlines' Managing Director of Hospitality & Planning Aaron McMillan and Dr. Patrice Harris, co-founder and CEO of eMed, a digital health company democratizing healthcare through its Digital-Point-of-Care™ platform, described how they came together with Abbott to help people fly confidently and conveniently with BinaxNOW COVID-19 Home Tests. United customers can take the proctored tests when traveling and have those results seamlessly confirmed by Abbott's NAVICA app and verified through United's Travel Ready Center.
Dr. Fiona Gupta of Mount Sinai Health System in New York highlighted how she uses the NeuroSphere Virtual Clinic, a first-of-its-kind technology in the U.S., that provides people with deep brain stimulation remotely, so physicians can optimize and adjust treatments over cellular or Wi-Fi while Parkinson's and chronic pain patients consult with them from the comfort of their living rooms.
The head of the University of Southern California's Center for Body Computing Dr. Leslie Saxon shared her vision of "Lifecare," which addresses everything from preventing sudden deaths to enhancing human performance.
Dr. Mary Rodgers, an Abbott virus hunter, shared how a first-of-its-kind network called the Abbott Pandemic Defense Coalition – stretching from Brazil to Senegal to Thailand – is working to identify new viruses and help stop them before they can spread.
Dr. Hakim Bouzamondo, head of nutrition research and development at Abbott, shared how the science behind the microbiome can optimize overall health with personalized nutrition.
The company said the Lingo portfolio of products under development and are not intended for medical use. They are not intended for use in screening, diagnosis, treatment, cure, mitigation, prevention, or monitoring of diseases. Lingo Portfolio of products are not for sale in the U.S.
April 12, 2024 
